Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.7%

11 terminated/withdrawn out of 75 trials

Success Rate

85.1%

-1.4% vs industry average

Late-Stage Pipeline

40%

30 trials in Phase 3/4

Results Transparency

49%

31 of 63 completed trials have results

Key Signals

31 with results8 terminated

Enrollment Performance

Analytics

Phase 3
15(25.0%)
Phase 4
15(25.0%)
Phase 2
14(23.3%)
Phase 1
11(18.3%)
N/A
5(8.3%)
60Total
Phase 3(15)
Phase 4(15)
Phase 2(14)
Phase 1(11)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (75)

Showing 20 of 75 trials
NCT02517684Phase 4Completed

Top-down Infliximab Study in Kids With Crohn's Disease

Role: collaborator

NCT02140736Completed

Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology

Role: lead

NCT00686946Unknown

The National Register of Antipsychotic Medication in Pregnancy (NRAMP)

Role: collaborator

NCT01007773Phase 2Withdrawn

Safety of Dexmedetomidine in Severe Traumatic Brain Injury

Role: collaborator

NCT01845441Phase 2Terminated

Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions

Role: collaborator

NCT01139866Completed

An Extension Trial to Evaluate Long-term Safety of SABER™-Bupivacaine for Pain Following Shoulder Surgery

Role: collaborator

NCT01052012Phase 3Completed

Bupivacaine Effectiveness and Safety in SABER® Trial

Role: collaborator

NCT02004613Phase 4Completed

Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery

Role: collaborator

NCT00654511Phase 4Completed

Dexmedetomidine for Immediate Perioperative Analgesia in Pediatric Patients Undergoing Tonsillectomy

Role: collaborator

NCT01543477Completed

Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia

Role: collaborator

NCT02539368Completed

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease

Role: collaborator

NCT02605642Completed

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade

Role: collaborator

NCT02245256Phase 4Completed

Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients

Role: collaborator

NCT02454530Terminated

Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study

Role: collaborator

NCT01158820Phase 4Completed

Alternative Sedation During Bronchoscopy

Role: collaborator

NCT02650193Phase 2Completed

A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.

Role: collaborator

NCT01473407Phase 3Completed

A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

Role: collaborator

NCT01473420Phase 3Completed

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

Role: collaborator

NCT01348412Phase 2Completed

Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure

Role: collaborator

NCT01059929Phase 4Terminated

Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)

Role: collaborator